Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone203-404-0410
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees63
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings data on Thursday, February, 28th. The company reported ($1.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.28) by $0.06. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
9 brokers have issued 1-year price targets for Biohaven Pharmaceutical's stock. Their forecasts range from $49.13 to $89.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $65.3913 in the next year. This suggests a possible upside of 8.7% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.
What is the consensus analysts' recommendation for Biohaven Pharmaceutical?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (3/6/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Overweight rating and raising our PT on BHVN to $75 from $65. The price target upgrade is a result of recent, but ongoing, due diligence in the space that refines our thinking on the evolving treatment paradigm. As a result, we have recast our model, now based on assumed use in certain target populations that we believe would be most appropriate for oral CGRPs. Namely, this includes the migraine patients contraindicated for triptans and those patients that fail to consistently respond to/tolerate triptans." (2/8/2019)
- 3. Canaccord Genuity analysts commented, "We are updating our BHVN model after the company recently reported its 2Q18 results and filed its 10-Q. We are not making any substantial changes to our model and are maintaining our DCF-based price target at $43, which represents ~20% upside potential from current levels. As we noted recently (see here), we believe the pullback from recent highs affords an opportunity to buy the stock ahead of upcoming data-related events in 4Q18." (8/17/2018)
Has Biohaven Pharmaceutical been receiving favorable news coverage?
News articles about BHVN stock have trended positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next few days.
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG) and Amarin (AMRN).
What other stocks do shareholders of Biohaven Pharmaceutical own?
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 48)
- Mr. James Engelhart, Chief Financial Officer (Age 55)
- Dr. Charles Conway, Chief Scientific Officer (Age 57)
- Mr. Clifford Bechtold, Chief Operating Officer
- Mr. Matthew DeLawder, Director of Accounting
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $60.16.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $2.66 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.
What is Biohaven Pharmaceutical's official website?
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
